Immunogenicity of repeat COVID-19 mRNA vaccinations in a patient with myasthenia gravis receiving mycophenolate, prednisone, and eculizumab
Vaccination can prevent infection and disease due to SARS-CoV-2. Early reports indicate that immune suppressed or immune compromised populations have reduced immune responses to US emergency use authorized (EUA) vaccines. Patients with autoimmune disorders are at risk for severe COVID-19, and are fr...
Main Authors: | Lisa C. Plymate, MD, Gregory Pepper, Maxwell P. Krist, David M. Koelle, MD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | Journal of Translational Autoimmunity |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2589909021000344 |
Similar Items
-
Eculizumab during Pregnancy in a Patient with Treatment-Refractory Myasthenia Gravis: A Case Report
by: Tuan Vu, et al.
Published: (2021-02-01) -
Mycophenolate mofetil as second line immunosuppressant in myasthenia gravis - a long-term prospective open-label study
by: Hanisch F, et al.
Published: (2009-08-01) -
Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis
by: Hai Xiao, et al.
Published: (2021-08-01) -
Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis
by: Jonathan P. R. Monteleone, et al.
Published: (2021-11-01) -
Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review
by: Waheed W, et al.
Published: (2022-07-01)